Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2010

01-04-2010

Gout, Hyperuricemia, and Parkinson’s Disease: A Protective Effect?

Authors: Alvaro Alonso, Kelly A. Sovell

Published in: Current Rheumatology Reports | Issue 2/2010

Login to get access

Abstract

Oxidative stress is potentially involved in the pathogenesis of Parkinson’s disease (PD). Serum uric acid, because of its antioxidant effect, might prevent the development of this neurodegenerative disorder. Indeed, a number of epidemiologic studies have consistently reported a strong inverse association between serum uric acid and the risk of PD. The risk of PD is also lower among individuals with gout. In addition, suggestive evidence from clinical studies shows high levels of uric acid as a marker of better prognosis in PD. Future research should determine the mechanisms underlying this association. This, in turn, could be used in the development of new preventive strategies and treatments for PD.
Literature
1.
Gabriel SE, Michaud K: Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11:229.CrossRefPubMed
2.
Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811–1821.CrossRefPubMed
3.
Hirtz D, Thurman DJ, Gwinn-Hardy K, et al.: How common are the “common” neurologic disorders? Neurology 2007, 68:326–337.CrossRefPubMed
4.
• Elbaz A, Moisan F: Update in the epidemiology of Parkinson’s disease. Curr Opin Neurol 2008, 21:454–460. This article provides an excellent review of the most recent findings on the epidemiology of PD.
5.
Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744–1754.CrossRefPubMed
6.
Larumbe Ilundáin R, Ferrer Valls JV, Viñes Rueda JJ, et al.: Case-control study of oxidative stress and plasma iron metabolism markers in Parkinson’s disease [in Spanish]. Rev Esp Salud Publica 2001, 75:43–53.
7.
Annanmaki T, Muuronen A, Murros K: Low plasma uric acid level in Parkinson’s disease. Mov Disord 2007, 22:1133–1137.CrossRefPubMed
8.
Andreadou E, Nikolau C, Gournaras F, et al.: Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 2009, 111:724–728.CrossRefPubMed
9.
Ahlskog JE, Uitti RJ, Low PA, et al.: No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord 1995, 10:566–573.CrossRefPubMed
10.
Davis JW, Grandinetti A, Waslien CI, et al.: Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 1996, 144:480–484.PubMed
11.
de Lau LM, Koudstaal PJ, Hofman A, Breteler MM: Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005, 58:797–800.CrossRefPubMed
12.
•• Weisskopf MG, O’Reilly E, Chen H, et al.: Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007, 166:561–567. This article provides results on the association of serum uric acid with the incidence of PD and, more importantly, meta-analyses results from prospective studies addressing this association.
13.
• Chen H, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2009, 169:1064–1069. The article analyzes the association of serum uric acid with PD in a cohort including both Caucasians and African Americans.
14.
Gao X, Chen H, Choi HK, et al.: Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 2008, 167:831–838.CrossRefPubMed
15.
•• Alonso A, García Rodríguez LA, Logroscino G, Hernán MA: Gout and risk of Parkinson disease: a prospective study. Neurology 2007, 69:1696–1700. This is the first published report of an inverse association between gout and risk of PD. The authors used data from a large computerized database.
16.
• de Vera M, Rahman MM, Rankin J, et al.: Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum 2008, 59:1549–1554. This article provides results from an analysis that confirmed previous observations on the inverse association of gout with PD risk in a larger population.
17.
Zhang W, Doherty M, Bardin T, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.CrossRefPubMed
18.
•• Schwarzschild MA, Schwid SR, Marek K, et al.: Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008, 65:716-723. This article provides secondary analysis of a clinical trial in patients with early PD, showing that serum uric acid is a strong predictor of disease and slower progression.
19.
• Ascherio A, LeWitt PA, Xu K, et al.: Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009, 66:1460–1468. This article provides another analysis from a clinical trial in early PD that confirms the value of uric acid as a predictor of clinical progression in PD.
20.
Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K: Uric acid associated with cognition in Parkinson’s disease. Parkinsonism Relat Disord 2008, 14:576–578.CrossRefPubMed
21.
Dehghan A, Köttgen A, Yang Q, et al.: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008, 372:1953–1961.CrossRefPubMed
22.
Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans agains oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858–6862.CrossRefPubMed
23.
Duan W, Ladenheim B, Cutler RG, et al: Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 2002, 80:101–110.CrossRefPubMed
24.
Spitsin S, Hooper DC, Leist T, et al.: Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001, 7:313–319.PubMed
25.
Scott GS, Spitsin SV, Kean RB, et al.: Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002, 99:16303–16308.CrossRefPubMed
26.
Shen H, Chen GJ, Harvey BK, et al.: Inosine reduces ischemic brain injury in rats. Stroke 2005, 36:654–659. (Published erratum appears in Stroke 2005, 36:1106.)
27.
Irizarry MC, Raman R, Schwarzschild MA, et al.: Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009, 6:23–28.CrossRefPubMed
28.
Euser SM, Hofman A, Westendorp RG, Breteler MM: Serum uric acid and cognitive function and dementia. Brain 2009, 132:377–382.CrossRefPubMed
29.
Markowitz CE, Spitsin S, Zimmerman V, et al.: The treatment of multiple sclerosis with inosine. J Altern Complement Med 2009, 15:619–625.CrossRefPubMed
Metadata
Title
Gout, Hyperuricemia, and Parkinson’s Disease: A Protective Effect?
Authors
Alvaro Alonso
Kelly A. Sovell
Publication date
01-04-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 2/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0083-4

Other articles of this Issue 2/2010

Current Rheumatology Reports 2/2010 Go to the issue

ReviewPaper

New Agents for the Treatment of Gout and Hyperuricemia: Febuxostat, Puricase, and Beyond

ReviewPaper

The Genetics of Juvenile Idiopathic Arthritis: What Is New in 2010?

Clinical trial report

Such Sweet Sorrow: Fructose and the Incidence of Gout

ReviewPaper

Gout, Hyperuricemia, and the Risk of Cardiovascular Disease: Cause and Effect?

ReviewPaper

Update on Biology: Uric Acid and the Activation of Immune and Inflammatory Cells

ReviewPaper

Remission in Juvenile Idiopathic Arthritis: Current Facts
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits